BRCA2 and neoplasm: Notably, these predicted pathogenic germline variants seem to be present at a much higher variant allele fraction (VAF) in the tumor samples compared to paired normals for the affected cases, showing significant loss of heterozygosity (one-sided Fisher exact test adjusted P values (false discovery rate, FDR), 4.60 × 10−5 and 4.18 × 10−5 for the BRCA2 variants and 1.98 × 10−14 for the BRIP1 variant).